MTOR and cancer: In sarcoma, IGF1R activation is known to activate the phosphatidylinositol-3-kinase/serine/threonine kinase Akt/Mammalian target of rapamycin (PI3K/Akt/mTOR) pathway which promotes cancer progression and metastasis [53].